CF Foundation grants Corbus $25M for Phase IIb study

The not-for-profit Cystic Fibrosis Foundation awarded Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) up to $25 million to support a planned Phase IIb trial of

Read the full 237 word article

User Sign In